Optical molecular imaging developer raises $3.1M in Series A funding

Jan. 2, 2015

Optical molecular imaging technology developer Lightpoint Medical has raised $3.1 million in Series A financing.

Optical molecular imaging technology developer Lightpoint Medical (Rickmansworth, Hertfordshire, England) has raised $3.1 million (£2 million) in Series A financing. Investors included Oxford Technology and business angel networks Cambridge Capital Group, London Business Angels, Envestors, Ruffena Capital, and crowdfunding platform SyndicateRoom.

Lightpoint Medical's technology, which is based on Cerenkov luminescence imaging, can help detect cancer in real time during surgery and reduce the need for repeat operations. The company has clinical trials underway in breast, prostate, and stomach cancers.

The company will use the investment funding to help bring its LightPath specimen analyzer for intraoperative tumor margin assessment and EnLight molecular imaging fiberscope to the U.S. and European markets in 2015.

About the Author

BioOptics World Editors

We edited the content of this article, which was contributed by outside sources, to fit our style and substance requirements. (Editor’s Note: BioOptics World has folded as a brand and is now part of Laser Focus World, effective in 2022.)